Topic hub
Switching treatment or staying put
How patients weigh a new preventive or a new therapy against the one they know, in migraine, dermatology and chronic conditions.
What did the panels say about switching treatment or staying put?
- #
82%
82% of US men are not open to getting a hair transplant, and none say they are very open — 82% of US men would not get a hair transplant, and 98% of those who see their hair thinning rule one out
base 200
- #
58.6%
58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. — Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
base 169
- #
66.1%
66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic — Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic
base 127
- #
12
For the Medicare Advantage members on this panel, keeping their own doctors is the one thing that would hold them to their insurer. — Medicare Advantage members would stay for their doctors, not a lower price: 12 of 23 name keeping their providers
base 23
- #
50%
50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. — Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them
base 146
What has Brox published on switching treatment or staying put?Newest first
-
82% of US men would not get a hair transplant, and 98% of those who see their hair thinning rule one out
82% 82% of US men are not open to getting a hair transplant, and none say they are very open (base 200)
Read -
Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
58.6% 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. (base 169)
Read -
Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic
66.1% 66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic (base 127)
Read -
Medicare Advantage members would stay for their doctors, not a lower price: 12 of 23 name keeping their providers
12 For the Medicare Advantage members on this panel, keeping their own doctors is the one thing that would hold them to their insurer. (base 23)
Read -
Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them
50% 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. (base 146)
Read -
Fear of side effects, not cost, keeps 53.6% of US migraine sufferers on the treatment they have
53.6% 53.6% of US migraine sufferers say worry about the side effects of something new is what would most keep them on their current treatment if a new one were available; 31.8% say what they have works well enough, 6.4% say their doctor has not suggested changing, 4.5% would switch as soon as something better appeared and 3.6% are unsure what a new drug would cost or whether insurance would cover it. (base 110)
Read
What do people ask about switching treatment or staying put?
- What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?
- 58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).Read the insight
- How do dermatologists decide when a patient with moderate eczema should move from topicals to a systemic?
- Insurance requirements and prior authorization are what most often make 66.1% of US dermatologists hold off moving an adult with moderate eczema from topicals to a systemic (n=127, October 2026), against 3.1% who name safety, while the trigger itself splits between a failed topical trial (51.6%) and itch or sleep loss (42.9%, n=126).Read the insight
- Where do Medicare Advantage members go when their plan is discontinued, and what would hold them?
- Asked what would most keep them with their insurer if their plan ended, 12 of 23 US Medicare Advantage members on the panel named keeping their own doctors and 2 named lower costs, September 2026.Read the insight
- How do physicians feel about biosimilar substitution, and where do they push back?
- Half of US physicians who manage biologics (50.0%, n=146, September 2026) are uncomfortable with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them, against 2.7% when they choose the switch themselves.Read the insight
- How do migraine sufferers decide between a new preventive and staying on what they have?
- Worry about a new drug's side effects is what would most keep 53.6% of US migraine sufferers on their current treatment, against 31.8% who say what they have works well enough (n=110, September 2026), and a covered once-daily pill that halves migraine days at no extra cost moved only 12.7% to try it.Read the insight
Other topics
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai